 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Protease Inhibitor Research
General Issues
- Protein Accumulation Might Cause Fat Deposits, Other Side Effects in HIV-Positive People Taking Protease Inhibitors, Study Says (July 18, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO - Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections - PI-Based Therapy Does Not Increase Glucose Intolerance, Gestational Diabetes in Pregnant, HIV-Infected Women (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections - Dual-Boosted Protease Inhibitor Regimen Shows Promise, but How Will It Be Used? (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Protease Inhibitors Not Associated With Fat Gain; Some Antiretrovirals Can Cause Fat Loss, Study Says (November 3, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO - HIV JournalView: Carotid Intima-Media Thickness Not Associated With Protease Inhibitor Use (July/August 2005)
From The Body PRO - My Friend Ritonavir: The Concept of "Boosting" (December 2004)
This research update reviews what we know about boosting HAART regimens with ritonavir (free registration required).
In The PRN Notebook - Triple PI Therapy May Help Heavily Treatment-Experienced Patients, But Pill Burden a Concern (October 2004)
Quick recap of a study in JAIDS.
In HIV Treatment ALERTS!, from The Center for AIDS - Protease Inhibitors Appear More Likely to Cause Atherosclerosis Than NNRTIs (July 15, 2004)
In The XV International AIDS Conference, from The Body PRO - Confort Study Supports Switch From Protease Inhibitor to Nevirapine (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO - NNRTI Resistance Occurs More Often at Lower Levels of Adherence Than Does PI Resistance (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO - Tipranavir Reduces Concentrations of Other Protease Inhibitors (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO - Changes to Labeling for Desyrel (Trazodone Hydrochloride) Tablets (PDF) (May 2004)
A "Dear Healthcare Professional" letter on potential interactions between this antidepressant and CYP3A4 inhibitors such as indinavir and ritonavir.
From U.S. Food and Drug Administration - Drug Development News: Gilead (May/June 2004)
A new prodrug technology targeting lymphocytes could all but revolutionize protease inhibitor therapy.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Protease Inhibitor Therapy: Boosted and Double-Boosted Options to the Fore (March 2004)
In The PRN Notebook - Triple-PI Regimens for Rescue Treatment (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Dual-PI Regimen Preferred Over Single-PI Regimen After Initial PI Failure (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Clinical Efficacy of Antiretroviral Combination Therapy Based on Protease Inhibitors or Non-Nucleoside Analogue Reverse Transcriptase Inhibitors: Indirect Comparison of Controlled Trials (January 31, 2004)
Three-drug regimens containing a protease inhibitor are found to more effectively suppress HIV than three-drug regimens containing NNRTIs.
In British Medical Journal - Endothelial Function in HIV-Infected Patients Receiving Protease Inhibitor Therapy: Does Immune Competence Affect Cardiovascular Risk? (November 2003)
Abstract of a study in the Quarterly Journal of Medicine.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Switching From PI to Nevirapine in Patients With Undetectable Viral Load Is Safe and Potent (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Association Between Protease Inhibitor Use and Increased Cardiovascular Risk in Patients Infected With Human Immunodeficiency Virus: A Systematic Review (September 12, 2003)
In Clinical Infectious Diseases - Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
In The New England Journal of Medicine - Better Suppression, Adherence With Once-Daily FTC/ddI/Efavirenz Than Most PI-Based Regimens (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Protease Inhibitors and Severe Adverse Events (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Switch to Nevirapine From Protease Inhibitor Lowers Triglycerides and Maintains Viral Load Suppression (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Older PIs Linked to Early Coronary Artery Disease (April 7, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Research From the 42nd ICAAC: Two PIs vs. Two PIs vs. Efavirenz (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Immune Reconstitution Is Similar in Antiretroviral-Naive Subjects Following 1 Year of Therapy With a Triple NRTI-Based or Protease Inhibitor-Containing ARV Regimen (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - 104 Weeks Outcome of Simplified Regimens in PI-Experienced Patients (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Study Finds Protease Inhibitors May Help Cause Lipodystrophy (October 30, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Study Examines Mortality Factors in HIV Patients on Protease Inhibitors (October 10, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Data From the 14th International AIDS Conference: Spare the PIs (October 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Perspective of HIV-Associated Coronary Heart Disease (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO - In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Saquinavir With Low-Dose Ritonavir Twice Daily (May 9, 2002)
From Canadian AIDS Treatment Information Exchange - Quality of Life, Emotional Status, and Adherence of HIV-1-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens (April 15, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - A New Look at Liver Toxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV (March 11, 2002)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project - Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Molecular Mechanism of I50V, I54L and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - In Vitro Model for Antiviral Activity for Amprenavir (APV)/Ritonavir (RTV) (December 19, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Impact on Fitness Conferred by Amprenavir Resistance Mutations (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered With Ritonavir (RTV) in Twice- and Once-Daily Regimens in HIV-Infected Patients (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Select HIV Protease Inhibitors Alter Bone and Fat Metabolism In Vitro (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Protease Inhibitors in Children: Combination Therapy Reduced Death by Two Thirds (November 23, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News - The Impact of First Line Therapies on Lipid Metabolism: The FRAMS Data (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - A Retrospective Cohort Study of the Durability of Antiretroviral Therapy Using Nevirapine versus Antiretroviral Therapy Using Protease Inhibitors (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Simplification of Protease Inhibitor-Containing HAART Regimen With Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Comparison of QD Protease Inhibitors (PIs): Estimated Cmin/IC50 (IQ) After Missed Dose Shows Agenerase Advantage (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Do Protease Inhibitors Increase the Risk for Coronary Heart Disease Among HIV-Positive Patients-Follow-Up Through June 2000 (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Efficacy and Safety of Switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Incidence and Predictors of Clinical Progression Among HIV-Infected Patients Experiencing Virologic Failure of Protease Inhibitor-Based Regimens (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Plasma Trough Levels Correlate with Distinct Genetic Mechanisms During the Development of Amprenavir Resistance (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  |
  |